Table 2.
Symptom | Placebo (%) | PAR/VAL (%) | RRa | P-valuea |
---|---|---|---|---|
Fatigue | 50.6 | 47.4 | 0.94 | NS |
Drowsiness | 56.0 | 51.6 | 0.92 | NS |
Inability to concentrate | 25.8 | 13.7 | 0.53 | <0.050 |
Nausea | 42.2 | 25.3 | 0.60 | <0.050 |
Dizziness | 33.7 | 21.1 | 0.62 | NS |
Constipation | 26.1 | 17.2 | 0.66 | NS |
Itching | 22.8 | 16.8 | 0.74 | NS |
Difficulty with urination | 12.0 | 6.3 | 0.53 | NS |
Confusion | 6.5 | 3.2 | 0.48 | NS |
Retching/vomiting | 20.0 | 11.7 | 0.59 | NS |
Note:
PAR/VAL compared with placebo.
Abbreviations: NS, nonsignificant; PAR/VAL, parecoxib/valdecoxib; RR, relative risk.